Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Navigating the patient maze – pharma’s evolving challenge
Chris O'Toole considers the challenges that pharma companies may face when adopting a more patient-centric approach.
-
Irish clinical trials company ICON gets €4m state funding
This article reports on ICON’s multimillion-euro funding from the Irish government to enhance its decentralised and hybrid trial capabilities.
-
Irish clinical trials company ICON gets €4m State funding for R&D
ICON has received €4m in R&D investment from the Irish government to further develop its technology for decentralised and hybrid clinical trials.
-
A multifaceted global approach to addressing antimicrobial resistance
Dr. Caroline Forkin, VP Clinical Research Services, considers the best approach to address antimicrobial resistance.
This article is taken from European Biopharmaceutical Review October 2021, pages 70-73. Samedan Ltd
-
The future of clinical trials
Dr. Greg Licholai, Chief Medical Information Officer, discusses key market trends, the future of clinical trials and the acquisition of PRA.
-
The waterfall effect of digital health technology on unifying healthcare and clinical research
Isaac R Rodriguez-Chavez contributes to the DPHARM Autumn 2021 newsletter, discussing the use of digital health to maximise efficiencies in decentralised clinical trials.
-
-
Top 10 factors to design and deploy a decentralised clinical trial
Dr. Isaac Rodriguez-Chavez considers the top 10 factors when designing and deploying a decentralised clinical trial.
This article is taken from International Clinical Trials August 2021, pages 8-10. Samedan Ltd.
-
Europe’s emerging biotechs: Challenges, opportunities and funding
John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.
-
Recruiting patients for real-world studies
William Maier, VP Rare Diseases, Drug Development Sciences, considers the benefits of digital recruitment campaigns for recruiting patients for real-world studies.
